Business & Management
Global

Business & Management Experts

Harry kirsch


Board of Directors
Novartis
France

Biography

    Mr. Harry Kirsch is Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and previously served as Chief Financial Officer of the Company’s Pharmaceuticals Division. At Novartis, he also served as Chief Financial Officer of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G's global pharmaceuticals business. Prior to that, he held finance positions in different categories of P&G's consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch studied industrial engineering and economics at the Universitaet Karlsruhe in Germany (Diplom Wirtschaftsingenieur).     Dr. Enrico Vanni, Ph.D. is Independent Non-Executive Vice Chairman of the Board at Novartis Inc. since February 22, 2013. He was Member of the Board of Directors at Novartis AG since 2011 till February 22, 2013. He qualifies as an Independent Non-Executive Director. He is Member of the Audit and Compliance Committee, and Chairman of the Compensation Committee at the Company. He began his career as a research engineer at International Business Machines Corp. in California, and joined McKinsey & Company in Zurich, Switzerland, in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led its European pharmaceutical practice and served as Member of the Partner review committee of the firm prior to his retirement in 2007. Since his retirement as Director of McKinsey & Company in 2007, Dr. Vanni has been an independent consultant. He is currently Member of several Boards of Directors in industries from healthcare to private banking, for nonlisted companies including Eclosion2, Denzler & Partners SA and Banque Privee BCP (Suisse) SA. Dr. Vanni holds an engineering degree in chemistry from Ecole polytechnique federale de Lausanne (the Federal Polytechnic School of Lausanne), Switzerland, a Ph.D. in chemistry from Universite de Lausanne, as well as a Master of Business Administration from INSEAD in Fontainebleau, France.     Mr. Harry Kirsch is Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and previously served as Chief Financial Officer of the Company’s Pharmaceuticals Division. At Novartis, he also served as Chief Financial Officer of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G's global pharmaceuticals business. Prior to that, he held finance positions in different categories of P&G's consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch studied industrial engineering and economics at the Universitaet Karlsruhe in Germany (Diplom Wirtschaftsingenieur).     Dr. Enrico Vanni, Ph.D. is Independent Non-Executive Vice Chairman of the Board at Novartis Inc. since February 22, 2013. He was Member of the Board of Directors at Novartis AG since 2011 till February 22, 2013. He qualifies as an Independent Non-Executive Director. He is Member of the Audit and Compliance Committee, and Chairman of the Compensation Committee at the Company. He began his career as a research engineer at International Business Machines Corp. in California, and joined McKinsey & Company in Zurich, Switzerland, in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led its European pharmaceutical practice and served as Member of the Partner review committee of the firm prior to his retirement in 2007. Since his retirement as Director of McKinsey & Company in 2007, Dr. Vanni has been an independent consultant. He is currently Member of several Boards of Directors in industries from healthcare to private banking, for nonlisted companies including Eclosion2, Denzler & Partners SA and Banque Privee BCP (Suisse) SA. Dr. Vanni holds an engineering degree in chemistry from Ecole polytechnique federale de Lausanne (the Federal Polytechnic School of Lausanne), Switzerland, a Ph.D. in chemistry from Universite de Lausanne, as well as a Master of Business Administration from INSEAD in Fontainebleau, France.

Research Interest

Finance Market

Global Experts from France

Global Experts in Subject

Share This Profile